Alzheimer’s disease (AD) is the most common form of dementia. It is estimated that one eighth of people aged of 65 suffer from AD worldwide. Primarily due to the ageing population, this number is projected to double every twenty years, reaching a staggering 139 million in 2050. Therefore, there is an urgent need for a risk detection tool of AD in early stages. PlasmarkAD®, a promising tool emerged, is translated from cutting-edge research efforts into risk prediction, aiming to achieve early and pre-symptomatic detection of AD by a simple blood test. Leveraging world-leading proteomics and machine-learning algorithms, PlasmarkAD® is capable of predicting AD 5-10 years before symptoms manifest, by detecting the level changes of 21 protein biomarkers in the blood, with an accuracy above 96 percent. PlasmarkAD® provides a less invasive, more direct and convenient ways to individuals for early understanding of their brain health.